排序方式: 共有4条查询结果,搜索用时 15 毫秒
1
1.
Neoadjuvant Therapy with Drug Arglabin for Breast Cancer with Expression of H-Ras Oncoproteins 下载免费PDF全文
Sergazy AdekenovAinur Zhumakayeva Vladimir PerminovBakhytzhan BekmanovKayrolla Rakhimov 《Asian Pacific journal of cancer prevention》2020,21(11):3441-3447
Backgrounds: In breast cancer, blocking of Ras signaling and inhibition of H-Ras is quite promising. H-Ras may become a target for farnesyl transferase inhibitors, and in combination with other immunohistochemical factors it will contribute to the progression of a breast tumor. Purpose: The aim of this study was to evaluate the effectiveness of neoadjuvant therapy for breast cancer with the inclusion of farnesyl transferase inhibitor, arglabin interfering with the expression and concentration of H-Ras oncoproteins. Methods: Depending on the presence of H-Ras oncoproteins after Western-blot hybridization, the patients were divided a negative and positive expression of H-Ras groups. Results: Correlation analysis of methods used for determining the expression ability and concentration of H-Ras oncoproteins (immunohistochemistry and Western-blot analysis) demonstrated substantial statistical relationship Rs=0.71, p=0.03. The H-Ras oncoproteins were absent in patients receiving either “Arglabin” or standard AC regimen. However, in the AC + Arglabin group, there was a varying degrees of positive concentration of H-Ras oncoproteins (Kruskal-Wallis=6.92; p=0.03). Conclusion: These results indicate that Arglabin attenuates H-Ras oncoproteins expression which is a promising therapeutic target for breast cancer. 相似文献
2.
Kayukova L. A. Uzakova A. B. Baitursynova G. P. Dyusembaeva G. T. Shul’gau Z. T. Gulyaev A. E. Sergazy Sh. D. 《Pharmaceutical Chemistry Journal》2019,53(2):129-133
Pharmaceutical Chemistry Journal - New antidiabetic agents are being sought because of the global problem with diabetes. Amidoxime derivatives are known to have antidiabetic activity.... 相似文献
3.
Zhangeldy S. Nurmaganbetov Leila I. Arystan Gulmira M. Muldaeva Leila S. Haydargalieva Sergazy M. Adekenov 《Pharmacological reports : PR》2019,71(6):1050-1058
BackgroundThe effects of chemical products on the nervous system have been studied by various scientists. In this work, the antiparkinsonian action of a water-soluble form of harmine hydrochloride was studied. The present studies aim to research antiparkinsonian action of the harmine hydrochloride original compound.MethodsTo achieve the objective of the study, the authors used haloperidol-induced catalepsy and a method of Parkinson’s syndrome (PS) induced by the MPTP (the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxin. The experiments were performed on rats and mice which were divided into groups of 10 animals.ResultsIt was established that harmine hydrochloride (HH), at a certain dose, eliminated haloperidol-induced catalepsy in rats and reduced oligokinesia and rigidity in the parkinsonism test in mice. Seven days after the experiment, the authors found the presence of rigidity in animals which had received the neurotoxin. It manifested itself in a shortened stride length compared to this parameter in intact controls.ConclusionsDuring the study the efficacy of harmine hydrochloride was equivalent to the effects of levodopa at a certain dose, which suggested that harmine hydrochloride compensated dopamine deficiency in the brain. 相似文献
4.
Hidayat Hussain Ivan R Green Ghulam Abbas Sergazy M Adekenov Wahid Hussain Iftikhar Ali 《Expert opinion on therapeutic patents》2013,23(9):689-702
ABSTRACTIntroduction: Protein tyrosine phosphatase 1B (PTP1B) inhibition has been recommended as a crucial strategy to enhance insulin sensitivity in various cells and this fact is supported by human genetic data. PTP1B inhibitors improve the sensitivity of the insulin receptor and have the ability to cure insulin resistance-related diseases. In the latter years, targeting PTP1B inhibitors is being considered an attractive target to treat T2DM and therefore libraries of PTP1B inhibitors are being suggested as potent antidiabetic drugs.Areas covered: This review provides an overview of published patents from January 2015 to December 2018. The review describes the effectiveness of potent PTP1B inhibitors as pharmaceutical agents to treat type 2 diabetes.Expert opinion: Enormous developments have been made in PTP1B drug discovery which describes progress in natural products, synthetic heterocyclic scaffolds or heterocyclic hybrid compounds. Various protocols are being followed to boost the pharmacological effects of PTP1B inhibitors. Moreover these new advancements suggest that it is possible to get small-molecule PTP1B inhibitors with the required potency and selectivity. Furthermore, future endevours via an integrated strategy of using medicinal chemistry and structural biology will hopefully result in potent and selective PTP1B inhibitors as well as safer and more effective orally available drugs. 相似文献
1